The Cost-Effectiveness of Rivaroxaban Plus Aspirin Compared with Aspirin Alone in the COMPASS Trial: A US Perspective.
Andre LamyJohn EikelboomWesley TongFei YuanShrikant I BangdiwalaJackie BoschStuart ConnollyEva LonnGilles R DagenaisKelley R H BranchWei-Jhih WangDeepak L BhattJeffrey ProbstfieldGeorg ErtlStefan StörkP Gabriel StegVictor AboyansIsabelle Durand-ZaleskiLars RydenSalim Yusufnull nullPublished in: American journal of cardiovascular drugs : drugs, devices, and other interventions (2023)
Rivaroxaban 2.5 mg BID plus ASA compared with ASA alone was cost-effective (high value) in the USA. COMPASS ClinicalTrials.gov identifier: NCT01776424.